Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
CJC-1295 is a 30-amino-acid peptide
Investigators commonly use 10 nM to 10 M concentrations in fibroblast, keratinocyte, and dermal-papilla cultures
Three volumes have become standard in research settings, each creating a different concentration that suits different needs
As with any pharmaceutical intervention, there are specific criteria and considerations for its use: Suitable candidates for cagrilintide treatment typically include: Adults with a Body Mass Index (BMI) of 30 or greater (classified as obese) Adults with a BMI of 27 or greater (overweight) with at least one weight-related comorbidity, such as hypertension, type 2 diabetes, or dyslipidemia Individuals who have not achieved sufficient weight loss through diet and exercise alone Patients without contraindications to amylin analogs or GLP-1 receptor agonists (when used in combination) It's crucial to note that cagrilintide is not recommended for certain groups, including: Pregnant or breastfeeding women Individuals with a personal or family history of medullary thyroid carcinoma Patients with Multiple Endocrine Neoplasia syndrome type 2 Those with a history of pancreatitis or severe gastrointestinal disorders Before initiating treatment with cagrilintide, a comprehensive medical evaluation is necessary
US$ 26.30
US$ 25.66
US$ 28.47
US$ 25.53
US$ 25.17
US$ 24.38